Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |3 October 2017

Different Effects of Screening on Prostate Cancer Death in Two Trials Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at Annals.org on 5 September 2017.
  • The full report is titled “Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.” The authors are A. Tsodikov, R. Gulati, E.A.M. Heijnsdijk, P.F. Pinsky, S.M. Moss, S. Qiu, T.M. de Carvalho, J. Hugosson, C.D. Berg, A. Auvinen, G.L. Andriole, M.J. Roobol, E.D. Crawford, V. Nelen, M. Kwiatkowski, M. Zappa, M. Luján, A. Villers, E.J. Feuer, H.J. de Koning, A.B. Mariotto, and R. Etzioni.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

What is the problem and what is known about it so far?

Prostate cancer occurs frequently, and the screening test does a good job of identifying men with the disease. Some cancer cases respond well to treatment, but others do not need treatment because the cancer does not respond or because it grows very slowly. It is difficult to separate cancer that responds from other cancer, so it is difficult to know when to treat and when not to treat. In this situation, screening involves tradeoffs. If screening is not done, more men will fail to get treatment that might prevent premature death because their cancer will go undetected until after it has spread. If screening is done, more men will get treatment that cannot help them, and some of them will have lower quality of life due to the treatment.

Why did the researchers do this particular study?

Two clinical trials—one in Europe and the other in the United States—provide the best information about whether screening lowers the risk for death due to prostate cancer. The European study found that men who were invited to be screened had fewer prostate cancer deaths than men who were not invited, but the American study found similar numbers of prostate cancer deaths in the 2 groups. The researchers of the current study wanted to figure out whether the results of the 2 trials were as different as they seemed.

Who was studied?

Both trials studied men aged 55 years or older, and both randomly invited some men to be screened but not others.

How was the study done?

In the 2 original studies, some men who were invited to be screened did not get screened, and some men who were not invited were screened anyway. These studies used traditional methods to compare the risk for death due to prostate cancer in men invited to have screening with the risk for death in men who were not invited to have screening. In contrast, the current study used a different approach to examine how the actual amount of screening in each group—regardless of whether men were invited to have screening—affected the risk for death due to prostate cancer.

What did the researchers find?

The 2 trials had remarkably similar results when the amount of screening actually received in each group was accounted for. Screening lowered the risk for prostate cancer death by 25% to 32% in men who were invited to have screening in the 2 trials compared with those who were not screened.

What were the limitations of the study?

The researchers used a simplified summary measure of how much screening was actually received in each trial group.

What are the implications of the study?

The European and American trials agree that screening lowers the risk for death due to prostate cancer compared with no screening.
This article was published at Annals.org on 5 September 2017.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Different Effects of Screening on Prostate Cancer Death in Two Trials. Ann Intern Med. ;167:I–16. doi: 10.7326/P17-9043

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2017;167(7):I-16.

DOI: 10.7326/P17-9043

Published at www.annals.org on 5 September 2017

©
2017 American College of Physicians
0 Citations

See Also

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
View MoreView Less

Related Articles

Pooled RCTs: Reanalysis accounting for screening intensity suggests that screening reduces prostate cancer mortality
Annals of Internal Medicine; 168 (2): JC5
Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts
Annals of Internal Medicine; 168 (1): 1-9
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Annals of Internal Medicine; 167 (7): 449-455
Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis
Annals of Internal Medicine; 167 (5): 341-350
View MoreView Less

Journal Club

Pooled RCTs: Reanalysis accounting for screening intensity suggests that screening reduces prostate cancer mortality
Annals of Internal Medicine; 168 (2): JC5
In prostate cancer, urinary and sexual function were worse with prostatectomy than active monitoring or radiotherapy
Annals of Internal Medicine; 165 (12): JC62
Radical prostatectomy reduced long-term mortality more than watchful waiting in early prostate cancer
Annals of Internal Medicine; 160 (12): JC10
Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer
Annals of Internal Medicine; 158 (2): JC9
View MoreView Less

Related Point of Care

Prostate Cancer
Annals of Internal Medicine; 163 (11): ITC1
View MoreView Less

Related Topics

Hematology/Oncology
Prostate Cancer

Hematology/Oncology, Prostate Cancer.

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×